CRISPR Therapeutics rises on upbeat quarter

Crispr Therapeutics AG

21/02/2024 13:41

** U.S.-listed shares  CRSP.O  of Swiss gene editing company
CRISPR Therapeutics rise 4.3% to $82.15 premarket
    ** Company posts Q4 profit of $1.10/shr vs loss of $1.41/shr
a year earlier
    ** Reports Q4 revenue of $201.2 mln vs est $131.6 mln - LSEG
    ** As of last close, company's U.S.-listed shares up 54.7%
in past 12 months

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com))